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Abstract: Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics 
(FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital 
and enabling large numbers of patients with severe mental illness (SMI) to be treated in the 
community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the 
paternalistic management of SMI symptoms to a patient-centered approach, which emphasized 
targets important to patients – psychosocial functioning, quality of life, and recovery. These 
drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders 
(DSM) categories. Evidence indicates that SGAs show an improved safety and tolerability profile 
compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, 
and there is less impairment of cognitive function and treatment-related negative symptoms. 
However, treatment with SGAs has been associated with a wide range of untoward effects, among 
which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The 
present clinical review aims to summarize the safety and tolerability profile of selected FGAs 
and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each 
drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical 
trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, 
iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasi-
done, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and 
tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” 
conceptual framework, which considers the longitudinal course and the clinical and therapeutic 
consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles 
should ideally be prescribed first. However, alongside with safety, efficacy should also be 
considered on a patient-tailored basis.
Keywords: antipsychotics, side effects, tolerability, safety, psychosis, psychiatry
Introduction
Severe mental illness (SMI), including major depressive disorder (MDD), bipolar 
disorder (BD), and schizophrenia spectrum disorders, represents a major public health 
issue, accounting for significant health and social and economic burden worldwide.1–5 
The chronic nature of SMI is characterized by recurring episodes,6,7 residual symptom 
burden, and a variable degree of cognitive dysfunction and functional impairment, 
which may persist even during periods of remission.8–13 In addition, growing evi-
dence indicates that acute, and especially chronic, manifestations are only partially 
addressed with first-line, approved treatments.14 More recently, the use of atypical 
or second-generation antipsychotics (SGAs) has been extended to cover a wide 
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range of psychiatric conditions besides schizophrenia and 
schizoaffective disorders. They have become especially 
popular as add-on treatment for patients with MDD who fail 
to adequately respond to antidepressants,15 for BD,16–18 and for 
behavioral symptoms associated with dementia.19,20 In addi-
tion, systematic evidence and meta-analysis indicate that 
SGAs are frequently used for several off-label indications;21,22 
they have been advocated as “multidimensional” agents.23
Since the serendipitous discovery of chlorpromazine 
(CPZ) for psychosis in 1952, first-generation antipsychotics 
(FGAs) have revolutionized psychiatric care, leading to 
across-the-board discharges from long-stay institutions 
and marked reductions in hospitalization rates.24 Until the 
1950s, patients suffering from SMI often required prolonged 
hospitalization, sometimes lifetime institutionalization, and 
were offered remedies with little or no evidence of benefit. 
The situation improved upon the development of FGAs, 
which allowed for safe and effective treatment in the com-
munity.25 The introduction of FGAs led to good control of 
behavioral and symptomatic domains in SMI (especially 
true for “positive” symptoms such as delusions and hal-
lucination), due to a heterogenous combination of strong 
D2 blockade and anticholinergic and antihistaminergic 
actions.26,27 Yet, this success turned out to be only partial 
because FGAs did not help and often had a deleterious impact 
on negative, cognitive, affective, and/or motor domains.28 
With the rediscovery of clozapine (CLO),29,30 SGAs, which 
combined potent (5HT2A) serotonergic blockade with potent 
but “fast-off” dopamine D2 blockade, were developed. The 
range of therapeutic indications was broadened, and there was 
a progressive shift from a paternalistic behavioral control of 
SMI symptoms to a more patient-centered approach, which 
valued improved psychosocial functioning and quality of 
life.31–33 Since the early 2000s, the development of antipsy-
chotics with partial agonism at dopamine D2 receptors has 
led several authors to speak of a class of “third-generation” 
antipsychotics.34 However, the lack of a third neuroreceptor 
system related to efficacy has for the most part prevented 
the widespread adoption of this terminology. Compared to 
the pharmacodynamic profile of FGAs, that of SGAs has a 
less specific antagonistic action at the D2 receptor and often 
a relatively stronger serotonin 5HT2A receptor action, as 
well as variable alpha adrenergic, antihistaminergic, and 
anticholinergic activities, plus exhibits a varying affinity 
at other (sub-) receptor types.35 Over the past 20 years, the 
main tolerability concerns have shifted from the sometimes 
disabling and always stigmatizing extrapyramidal adverse 
effects of FGAs to cardiometabolic issues that affect health 
and life span and are associated – to varying degrees – 
with SGAs.35–39
Despite the widespread use of SGAs, many concerns have 
been raised regarding their safety and tolerability. Safety 
issues vary according to patient populations and across 
various compounds. For example, the appropriateness of 
SGA use has been debated in patients with dementia due to 
an increased incidence of cerebrovascular events and death 
compared to placebo.21,40 Furthermore, different SGAs dif-
ferentially induce treatment-emergent weight gain and meta-
bolic disturbances,41 among other side effects, thus affecting 
drug tolerability and safety36,42 to different degrees. Given 
that these drugs usually need to be taken indefinitely, toler-
ability43 and treatment adherence,44,45 and their relationship 
to outcomes in SMI,46 must always be considered alongside 
with efficacy.
Hence, the main objective of this review is to critically 
review the literature in order to provide clinically oriented 
state-of-the-art coverage of the safety and tolerability 
profile of selected FGAs and SGAs in SMI. The second-
ary objective is to provide a succinct overview of possible 
pharmacological mechanisms underpinning differences 
in tolerability and safety among SGAs and to interpret 
tolerability data according to the “behavioral toxicity” 
framework.47–49 This refers to treatment-induced alterations 
in mood, perception, cognition, and psychomotor function, 
all of which can potentially worsen illness course.50 Impor-
tantly, some of these untoward effects may persist long after 
drug discontinuation.50,51 Such phenomena are captured by 
the term iatrogenic comorbidity,50,51 a negative outcome of 
the treatment of psychosis whose unfortunate pervasiveness 
is this review hopes to reduce.
Methods
This is a narrative review of selected side effects (Table 1) based 
on a PubMed/MEDLINE database search on December 20, 
2016, using the following search terms: “second-generation 
antipsychotic” OR “SGA*” OR “atypical antipsychotic” 
cross-referenced with “drug-related side effects and adverse 
reactions” [Mesh] OR “specific side effects” (Table 1), with-
out publication date or language limit. We synthesized the 
evidence in a best evidence synthesis and considered large-
scale observational studies, randomized controlled trials 
(RCTs), previous meta-analyses, or systematic reviews 
(SRs), and single-drug package insert data as well. When 
none of the former options were available, we also considered 
case reports for preliminary emerging evidence not otherwise 
covered in the literature.
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Adverse effects and behavioral toxicity 
related to antipsychotic use
Table 2 summarizes the selected pharmacodynamic receptor 
profile of several FGAs and all marketed SGAs in Europe 
and the US. A detailed overview of drug specific tolerability 
and safety profiles is reported in Table 3. We considered 
selected FGAs (CPZ, haloperidol (HAL), loxapine [LOX], 
molindone [MOL], and perphenazine [PER]) and the SGAs 
amisulpride (AMI), aripiprazole (ARI), asenapine (ASE), 
brexpiprazole (BRE), cariprazine (CAR), CLO, iloperidone 
(ILO), lurasidone (LUR), olanzapine (OLA), paliperidone 
(PALI), risperidone (RIS), quetiapine (QUE), sertindole 
(SER), and ziprasidone (ZIP).
Sedation
Sedation can be a therapeutic target in the acute treatment 
of SMI patients presenting with agitation or severe behav-
ioral symptoms but is also a safety concern and should be 
avoided in the long-term treatment due to its relationship with 
adverse effects on cognitive performance, physical activity/
sedentary behavior/body weight, and patients’ satisfaction 
with therapy, among others, as shown in an influential meta-
analysis and randomized clinical trials.28,52 Sedation is linked 
with the blockade of histaminergic receptors and is highest 
for CLO, zotepine, and CPZ, gradually decreasing from QUE, 
OLA, ZIP, ASE, HAL, and RIS to LUR, ARI, ILO, SER, 
PALI, and AMI, as shown in a comparative meta-analysis 
of trials of acute antipsychotic use in schizophrenia.28 Rather 
than being sedative, CAR shows an activating profile accord-
ing to its high number in a number needed to harm trial.53 
In BD, a recent meta-analysis showed surprisingly compa-
rable sedation between ARI and other SGAs,54 which may be 
an artifact due to frequent benzodiazepine coadministration in 
the beginning of trials in acute BD mania or may be associ-
ated with ARI itself, particularly at doses .20 mg/day.
Cognitive impairment
FGAs and SGAs can both impair cognitive functions in the 
first-episode schizophrenia, with the former being linked to 
a worse profile, as shown in a meta-analysis.55 The cognitive 
effect of antipsychotics is a complex domain, which can be 
influenced by baseline cognitive ability,56 plus anxiety, mood, 
positive, negative, and residual symptoms in patients with 
schizophrenia. Considered as a unique domain, cognitive 
performance is negatively influenced by high doses of drugs 
with strong anticholinergic properties and with strong D
2
 
blockade in patients with schizophrenia, as shown by several 
RCTs.57,58 Consequently, while RIS and HAL can impair cog-
nitive function through a decrease in dopamine transmission, 
CLO, OLA, and QUE exert similar effects perhaps through 
more potent anticholinergic activity and also because they are 
potent D2 blockers in their own right (but for shorter periods 
of time). Moreover, it is not clear whether coadministration 
of anticholinergic drugs for extrapyramidal symptoms (EPS) 
and dampening of motivation may confound net effect of 
antipsychotics on cognition. Since cognitive function ben-
efits indirectly from an improvement in hallucinations and 
thought disorganization59 due to antipsychotic administration, 
the net effect on cognition is often null, as reported in RCTs 
and SRs.60,61 However, cognition is frequently reported only 
as a secondary outcome, or not reported at all, as shown in 
SRs of RCTs of SGAs in schizophrenia.62,63 It has been hoped 
Table 1 Main treatment-emergent adverse events related to the 
use of antipsychotics
Adverse effects and behavioral toxicity of antipsychotics at 
therapeutic doses
Sedation
Cognitive impairment
weight gain and obesity
Metabolic syndrome and its components (waist circumference, 
dyslipidemia, high fasting blood sugar, diabetes mellitus, and 
hypertension)
Neuromotor adverse effects (ePS, bradykinesia, dystonia, akathisia,  
and TD)
Seizures
QTc prolongation, HRv, and SCD
Hypotension
Myocarditis and cardiomyopathy
Coronary heart disease and stroke
Pneumonia and acute respiratory failure
Pulmonary embolism and venous thromboembolism
Gastrointestinal adverse effects (eg, nausea, vomiting, diarrhea, and 
constipation)
Dry mouth, sialorrhea, and dental caries
Liver toxicity
Urinary and kidney dysfunction
Leucocytopenia, agranulocytosis, and thrombocytopenia
Osteopenia, osteoporosis, and fractures
Falls
Binge eating, impulse discontrol, and gambling
Tobacco use and smoking
Sexual and reproductive system dysfunction
endocrine adverse effects (diabetes ketoacidosis, hypothyroidism, and 
hyponatremia)
Hyperprolactinemia and prolactinoma
Breast and cervical cancers
Malignant neuroleptic syndrome
Use in pregnancy and breastfeeding
withdrawal syndromes
Rebound syndromes
Abbreviations: ePS, extrapyramidal symptoms; TD, tardive dyskinesia; HRv, heart 
rate variability; SCD, sudden cardiac death.
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that ARI would, unlike other antipsychotic drugs, improve 
cognition. The drug may ameliorate pre-attentive functions,64 
possibly due to both its partial D2 agonism and its almost 
absent affinity to cholinergic receptors. However, clinical 
data from RCTs do not seem to confirm such a priori expecta-
tions, as they show no change in cognitive function when ARI 
or BRE are administered to patients with schizophrenia.65 
Furthermore, no difference in effects on cognitive function 
emerged when ARI was meta-analytically compared with 
other antipsychotics in schizophrenia.66
weight gain and obesity
Although most high-potency FGAs have relatively little 
weight gain potential, low-potency FGAs and most SGAs can 
substantially increase the risk of weight gain and ultimately 
of obesity in schizophrenia.36,42,67 However, the weight gain 
potential differs substantially among SGAs, and certain 
FGAs can even induce more weight gain than specific SGAs. 
In particular, while HAL, ZIP, LUR, ARI, BRE, CAR and 
AMI are associated with little weight gain, at least in chronic 
patients who are often already overweight, PALI, RIS, and 
QUE induce moderate weight gain, SER, CPZ, ILO, strongly 
increase body weight, with extreme body mass index (BMI) 
increases with treatment by CLO, zotepine, and OLA.28,68 
There seems to be less consensus regarding ASE, which has 
been described by different SRs as either one of the SGAs 
with least weight gain28 or as a weight neutral drug68 in 
schizophrenia. In any case, all antipsychotics are associated 
with often substantial weight gain, especially evident when 
treating antipsychotic-naïve patients.69,70
Metabolic syndrome and its components 
(waist circumference, dyslipidemia, 
diabetes mellitus, and hypertension)
Metabolic syndrome is defined by the presence of three or 
more of five criteria, including increased waist circumfer-
ence (central obesity), elevated blood pressure, low high-
density lipoprotein cholesterol, hypertriglyceridemia, and 
hyperglycemia.71 Since patients with metabolic syndrome 
are at an increased risk of cardiovascular disease (CVD),71 
drugs with a more favorable metabolic profile are preferred 
in BD and schizophrenia.36 Antipsychotics can directly or 
Table 2 Neuroreceptor binding profiles of antipsychotics
Drug Ki D2 Ki 5HT1A Ki 5HT2A Ki 5HT2C Ki α1 Ki α2 Ki H1 Ki M2
CPZ 3 2,115 4.06 32.5 2.6 750 3 244
HAL 2.6 1,800 61 4,700 17 600 260 .10,000
LOX 9.8 NA 2 NA 250 NA 14.9 NA
MOL 120 3,797 5,000 .10,000 2,500 625 .10,000 NA
PER 1.4 421 5 132 10 500 8 NA
AMi 1.3 .10,000 2,000 .10,000 7,100 1,600 .10,000 NA
ARi ±0.7 ±5.5 8.7 22 26 74 30 3,510
ASe 1.3 2.5 0.06 0.03 1.2 1.2 1 .10,000
BRe ±0.3 ±0.12 0.47 NA 3.8 0.59 19 NA
CAR ±0.5 ±2.6 18.8 134 155 NA 23.2 .10,000
CLO 210 160 2.59 4.8 6.8 158 3.1 204
iLO 6.3 168 5.6 14 4.7 4.7 437 3,311
LUR 1 ±6.4 0.5 NA NA 11 .10,000 .10,000
OLA 20 610 1.5 4.1 44 280 0.1 622
PALi 2.8 480 1.2 48 10 80 3.4 .10,000
RiS 3.8 190 0.1 32 2.7 8 5.2 .10,000
QUe 770 300 31 3,500 8.1 80 19 630
SeR 2.7 2,200 0.14 6 3.9 190 440 NA
ZiP 4.8 ±3.4 0.4 1.3 10 154 4.6 .3,000
Effects related to receptor blockade
ePS, 
hyperprolactinemia, 
sexual dysfunction, 
and cognitive 
dysfunction
Anxiolytic and 
antidepressant 
effects
Lower 
incidence of 
akathisia and 
parkinsonism
weight 
gain and 
metabolic 
effects
Hypotension, 
priapism, 
retrograde 
ejaculation, 
and low libido
Antidepressant Appetite, 
sedation, cognitive 
dysfunction, and 
weight gain
Cognitive 
dysfunction, urinary 
retention, glaucoma, 
constipation, and 
dry mouth
Notes: Lower Ki (ie, nanomolar concentration at which 50% of the respective receptor type is occupied) means higher affinity. Light gray, FGAs; ±, partial agonism for the 
specific receptor. Italics represent FGAs. Data from Correll.35
Abbreviations: CPZ, chlorpromazine; HAL, haloperidol; LOX, loxapine; NA, not applicable; MOL, molindone; PeR, perphenazine; AMi, amisulpride; ARi, aripiprazole; ASe, 
asenapine; BRe, brexpiprazole; CAR, cariprazine; CLO, clozapine; iLO, iloperidone; LUR, lurasidone; OLA, olanzapine; PALi, paliperidone; RiS, risperidone; QUe, quetiapine; 
SER, sertindole; ZIP, ziprasidone; EPS, extrapyramidal symptoms; FGAs, first-generation antipsychotics; FGA, first-generation antipsychotics.
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indirectly adversely affect cardiometabolic health in various 
ways, ranging from increasing appetite and food intake72 to a 
more sedentary lifestyle linked to sedation or EPS;73 however, 
it has been shown that cardiometabolic adverse effects of 
antipsychotics are to some degree independent of lifestyle 
parameters.74 Polypharmacotherapy increases the risk of 
metabolic syndrome.38 A meta-analysis showed that both 
FGAs and SGAs increase the risk of metabolic syndrome 
compared to a no drug condition in SMI.36 According to the 
same meta-analysis and individual studies, the metabolic 
liability of antipsychotics ranges broadly, the lowest risk 
associated with ARI, BRE, CAR, LUR, ZIP, and high-
potency FGAs (HAL) and the highest risk associated with 
CPZ, CLO, OLA, and QUE. All other antipsychotics are 
considered as having a medium/intermediary risk.36 Longer 
term data are still lacking with the newest SGAs, BRE, 
and CAR.
Neuromotor side effects (ePS, 
bradykinesia, dystonia, akathisia, and 
tardive dyskinesia)
EPS, including bradykinesia, muscle rigidity, tremor, dysto-
nia, akathisia, and tardive dyskinesia (TD), are linked to the 
ratio of D
2
 receptor to 5HT2A receptor binding. According 
to several meta-analyses,28,75 the highest incidence of EPS in 
patients with schizophrenia occurs with HAL, with moderate 
EPS being observed with RIS, PALI, and LUR, down to CPZ; 
milder EPS being observed with ASE, ZIP, AMI, ILO, and 
ARI; and still milder EPS being observed with QUE, OLA, 
SER, and CLO. Although CAR is a partial D2 agonist, 
it seems to increase the risk of EPS according to a recent 
meta-analysis across SMI,76 perhaps due to relatively weak 
5HT2A antagonism (or more antagonism than agonism). 
Perhaps because of illness-induced serotonin disturbance, 
BD patients, especially in depression, have been found in 
one meta-analysis to be more vulnerable to acute movement 
disorders secondary to antipsychotics than patients with 
schizophrenia.77
Akathisia, defined as a compelling need for constant 
motion, associated with marching up and down, crossing 
and uncrossing the legs when sitting, and improving after 
drug dose reduction or coadministration of benzodiazepines, 
should be differentiated from pseudoakathisia.78,79 The latter 
is characterized by inner restlessness as a sign of pharmaco-
dynamic or pharmacokinetic rebound-induced restlessness 
and improves when the dose of an antipsychotic is increased. 
Akathisia can occur with both FGAs and SGAs, but FGAs 
are more likely to produce clinically relevant akathisia as 
per one meta-analysis.55 Comparative meta-analyses show T
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that ARI induces more akathisia than OLA in schizophrenia 
and BD, CLO and RIS more than ZIP, and RIS more than 
SER.54,75 It should be noted that some overlap between 
akathisia and pseudo-akathisia labeling may have influenced 
these results.
Compared to FGAs, an up to sixfold lower incidence of 
TD, tardive dystonia, and tardive akathisia occurs with SGAs 
in schizophrenia.80,81 Some evidence pointed to a possible 
increased risk for TD in populations with BD.82 Nonetheless, 
data on the incidence of TD in BD are substantially lack-
ing or else are totally missing as in the case of long-acting 
depot RIS.83 ARI has been associated with TD, in particular 
when high doses are prescribed, in female elderly patients 
in particular.84
While an association between some genetic polymor-
phisms85,86 and TD has been described in patients with schizo-
phrenia, there is no consensus about a genetic predisposition 
to TD.87 On the other hand, several clinical variables have 
consistently predicted TD occurrence in schizophrenia in 
observational studies, RCTs, and reviews; these include anti-
cholinergic medication; older age; intermittent antipsychotic 
treatment; high cumulative dose; higher negative, cognitive, 
and affective symptoms; and early movement side effects.88–91 
At present, no specific SGA can be considered as conferring 
a higher TD risk than others in schizophrenia.92
Seizures
A World Health Organization (WHO) adverse drugs reaction 
database study hypothesized a higher risk for seizures not 
only with SGAs than FGAs, especially with CLO, but also 
with OLA and QUE.93 Yet, this contrasts with the results 
of a recent meta-analysis finding a slightly increased risk 
for seizures with FGAs compared to SGAs. Still, CLO 
seems associated with a higher seizure risk in patients with 
either BD or schizophrenia compared to other SGAs.94,95 
One population-based study reported an increased risk of 
antipsychotic-related seizures with CLO and HAL, finding a 
lower risk with ARI compared with RIS. Clinical variables, 
such as younger age, a diagnosis of schizophrenia versus BD, 
and higher antipsychotic doses may help to identify subpopu-
lations at higher risk for treatment-emergent seizures, but no 
causal inference can be made based on cross-sectional data.95 
While a precise mechanism is unknown, a role of D2 and D3 
receptors has been suggested.96
QTc prolongation, heart rate variability, 
and sudden cardiac death
Patients with schizophrenia have shown a proneness to 
rhythm alterations, such as Brugada syndrome.97 In addition 
to such a predisposition, cardiac electrical activity can be 
altered by antipsychotic use, resulting in QTc prolonga-
tion, even in younger patients, in particular in women.98,99 
In adults, QTc prolongation is generally clinically relevant 
when QTc is .500 milliseconds or when QTc increases 
by $60 milliseconds from drug-free baseline,39 resulting in an 
increased risk of torsades de pointes and sudden cardiac death 
(SCD). QTc alterations may start as early as 2 weeks after 
the beginning of antipsychotic treatment in the first-episode 
schizophrenic patients.100 In a recent, nationwide study, use 
of any antipsychotics was associated with a 1.5-fold increased 
risk of ventricular arrhythmia and/or SCD, being somewhat 
higher with FGAs (odds ratio [OR] =1.66, 95% CI 1.43–1.91) 
than with SGAs (OR =1.36, 95% CI 1.20–1.54),101 with an 
increased risk of up to 5.8-fold, depending on the definition 
of SCD.39
In an observational study of patients with BD, SGAs were 
shown to decrease heart rate variability (HRV), in particular 
those drugs with high affinity for the D2 receptor.102 Since 
HRV is a recognized predictor of SCD, routine monitoring 
of HRV may help in identifying at-risk subjects and possibly 
prevent SCD.103 According to several meta-analyses and 
individual studies on schizophrenia, ARI, BRE, CAR, and 
ILO do not seem to have a clinically relevant effect on QT 
in schizophrenia, whereas ASE, CLO, OLA, and QUE may 
have a moderate effect, and finally, AMI, PALI, RIS, ZIP, 
and SER as well as thioridazine have been associated with 
the highest QT prolongation.28,104–106
Hypotension
Hypotension is a relevant side effect, which can be compli-
cated with syncope. Falls sometimes lead to hip fracture, 
transient ischemic attacks, myocardial infarction in rare occa-
sions, and, ultimately, to death in the most severe cases.107 
Orthostatic (or postural) hypotension is thought to be medi-
ated by α-1 receptor blockade and should be expected from 
antipsychotics with a high affinity to this receptor, such as 
ILO, ZIP, RIS, QUE, ASE, HAL, CPZ, and PER,108 according 
to animal models. In human beings, CLO, among SGAs, most 
increases the risk of hypotension, especially at the beginning 
of treatment, which is the reason behind low initial doses.94
Myocarditis and cardiomyopathy
Although not a frequent event, myocarditis risk is highest with 
CLO, being associated with troponin and C-reactive protein 
elevation, and eosinophilia.109 Emerging but sparse case reports 
also describe cases of myocarditis with QUE.110,111 In general, 
regular medical examination as well as blood examination 
and routine electrocardiography when symptoms arise 
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(fatigue, palpitations, arrhythmias, shortness of breath upon 
exertion or at rest, dizziness) can help detect myocarditis and 
cardiomyopathy early.112 Early data suggested that successful 
rechallenge with CLO after myocarditis may be possible in 
some cases.113
According to a large observational study, cardiomyopathy 
may occur as well with CLO, potentially leading to heart 
failure.114 Echocardiography is the gold standard procedure 
to detect and monitor cardiomyopathy.
Coronary heart disease and stroke
Subjects affected by SMI, including BD and schizophrenia, 
have consistently been shown to have an up to twofold 
increased risk of stroke and acute myocardial infarction 
(AMI), according to several meta-analyses.115–118 FGAs and 
SGAs appear to contribute to the increased risk of stroke 
(OR =1.58, 95% CI 1.01–2.49)119 and AMI (OR =1.88, 95% 
CI 1.39–2.54).120 Comparative data providing information 
about different SGAs are sparse, and in particular, the 
cardiovascular safety of newer SGAs, such as ILO, LUR, 
BRE, and CAR, is missing. In the elderly, higher mortality 
with FGAs than SGAs seems to be partially explained by a 
greater risk for stroke and AMI (in addition to ventricular 
arrhythmias and hip fracture).121 Broadly, in SMI, HAL, CPZ, 
OLA, RIS, and QUE have shown the strongest association 
with cardiovascular events.69,122–126 The main mechanism 
through which antipsychotic agents increase CVD rates is 
through their metabolic effects on weight and glucose and 
lipid metabolism;36,37,127 however, some direct toxic action has 
also been hypothesized based on animal models, in particular 
involving potassium and calcium channel currents.128–130
Pneumonia, acute respiratory failure, 
and sleep apnea
Two large observational studies suggest that, in patients with 
schizophrenia, CLO may result in an increased incidence 
of pneumonia, which persists after CLO is withdrawn and 
returns when it is reintroduced. This has been associated with 
sialorrhea.131–133 There is evidence suggesting that this risk 
is dose related, in particular with CLO, and is higher in the 
first weeks of therapy and in elderly patients.132,134 Polyphar-
macotherapy may further increase pneumonia risk.132 While 
ARI and ZIP do not seem to increase the risk of pneumonia, 
OLA and RIS increase pneumonia occurrence more than 
QUE in the elderly population,135 but no dose-dependent 
effect has been observed.132 A meta-analysis including 
a wider group of patients beyond schizophrenia and BD 
clearly showed that both FGAs and SGAs increase the risk 
of pneumonia.136 More meta-analytic evidence suggested that 
pneumonia accounts for the higher mortality of FGAs over 
SGAs.137 Most importantly, this difference between FGAs 
and SGAs was confirmed in both elderly and young adult 
populations.136 Finally, when prescribing antipsychotics to 
patients with chronic obstructive pulmonary disease, a fre-
quent comorbidity in BD and schizophrenia,138,139 respiratory 
function should be strictly monitored since there is a .1.5-
fold increased risk of acute respiratory failure.140 In case of 
overdose of AP, respiratory depression can occur as well, 
due to central sedation and peripheral respiratory muscle 
impairment.141
Sleep apnea moreover has been shown to be more fre-
quent in patients taking SGAs compared with those not on 
SGAs138 even after analyses were adjusted for several relevant 
confounding factors in a large observational study.142 It could 
be argued that compounds that increase the risk of weight 
gain consequently increase the risk of sleep apnea; no specific 
SGA, however, has shown a worse profile than others.
Pulmonary embolism and venous 
thromboembolism
Patients with schizophrenia on antipsychotic treatment show 
a global hypercoagulability state.143 Pulmonary embolism is 
a severe adverse event that can occur with antipsychotics, 
with the concomitant prescription of both FGAs and SGAs 
increasing the risk from potential substantial harm to a four-
fold increased risk, as clearly shown in large observational 
studies and a meta-analysis.144,145 Similarly, considering both 
pulmonary embolism and venous thromboembolism together, 
some evidence suggests that low-potency FGAs and SGAs 
have a worse safety profile than high-potency FGAs.145–147 
However, only sparse data are available for individual drugs 
or specific diagnostic groups.145 Special attention should be 
paid in pregnancy and the immediate postpartum, two condi-
tions at increased risk for thrombosis per se.
Gastrointestinal adverse effects
A cross-sectional study of patients with schizophrenia showed 
that among all antipsychotics, CLO seems to induce the most 
severe constipation, prolonging colon transit time by up to 
almost five times, irrespective of gender, age, ethnicity, or 
length of treatment, undermining treatment adherence.148 This 
is likely due to the anticholinergic action149 and is a dangerous 
side effect which patients should be monitored for, given the 
reduced pain sensitivity demonstrated in schizophrenia.150,151 
OLA, CLO, and low-potency FGAs substantially impair 
colon transit, while drugs with low affinity to cholinergic 
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receptors, such as BRE, CAR, LUR, and PALI, do not.152 
Conversely, according to a recent meta-analysis on schizo-
phrenia, ARI has been reported to reduce constipation when 
co-administered with other antipsychotics.153 D
2
 antagonists 
have been reported to reduce nausea (the early FGAs were 
widely used for nausea of pregnancy),153 but the partial D2 
agonists, such as CAR, BRE, and ARI, can induce nausea, 
typically within the first 4 weeks of treatment.154,155
Dry mouth, drooling/hypersalivation, and 
dental caries
Dry mouth is an anticholinergic side effect, most frequent 
with CLO, OLA, QUE, and low-potency FGAs, that increases 
the risk of dental caries according to a large population-based 
study.156 Sialorrhea is a frequent and paradoxical side effect 
of CLO.157 Hypersalivation substantially impairs quality of 
life and may interfere with social functioning, but has, how-
ever, been reported to prevent dental caries.156 Yet, intense 
sialorrhea may bear important consequences, such as an 
increased risk for aspiration pneumonia.133 ARI has been 
reported to reduce drooling/hypersalivation, according to a 
meta-analysis,153 when antipsychotic polypharmacotherapy 
is used in schizophrenia.
Hepatotoxicity
The precise pathogenesis of liver damage with the use of 
antipsychotics is unknown. Several hypotheses have been 
proposed, but no unique mechanism has been detected 
since FGAs and SGAs comprise a group of molecules with 
largely different chemical structures, pharmacokinetics, and 
pharmacodynamics.158 Continuous use of antipsychotics is 
associated with abnormal liver function tests in up to 78% 
of patients, as shown by an SR.158 Generally, such alterations 
consist of elevated transaminases or cholestatic indices, 
which often occur within the first 6 weeks of treatment, 
remaining stable or resolving with continuous treatment.158 
Although asymptomatic liver enzyme abnormalities may be 
common, significant liver enzyme elevations are rare, but 
can occur with OLA, QUE, and RIS.159 CPZ has been most 
frequently associated with acute liver injury, even resulting 
in fatal hepatic failure, but such events are rare with other 
antipsychotics.158 Sparse comparative data are available, 
but CLO seems to confer a relatively high risk of liver dam-
age, in particular compared with HAL.160 SGAs have been 
associated with chronic liver disease in patients with BD 
in a large observational study.161 During the first 3 years 
of antipsychotic treatment in patients with the first-episode 
schizophrenia, nonalcoholic fatty liver disease was associated 
with the presence of the major components of metabolic 
syndrome in an RCT.162 Liver function should be monitored 
in patients administered SGAs.163 Predisposing factors to 
liver damage include not only older age, high daily dosage/
serum concentrations, alcohol abuse, and a history of hepatic 
disease160 but also some of the evidence-based combination 
treatments for BD, such as valproate.164 PALI, which does 
not undergo first-pass hepatic metabolism, and ZIP, which 
is only partially metabolized by cytochrome P450 enzymes, 
are safest for the liver.
Urinary and kidney function
PALI, CLO, ILO, OLA, QUE, and RIS are excreted in urine, 
while ARI and ZIP are excreted in feces so that these two 
drugs do not require dose adjustment in patients with renal 
impairment, at least regarding their oral formulations.39 Con-
versely, LUR requires dose adjustment when renal failure 
is present, and CAR and AMI, which are solely excreted by 
the kidneys, should be avoided in case of renal failure.165 
Moreover, since electrolyte disturbances can occur when 
renal function is impaired, AMI and SER should be used with 
caution and with accompanying electrolyte monitoring due to 
potential cardiac toxicity. Drugs with strong anticholinergic 
properties, such as CLO, OLA, and low-potency FGAs, can 
induce acute urinary retention, but urinary acute retention 
can also occur with ZIP or RIS, via central dopaminergic 
and serotoninergic mechanisms as described in an SR.166 
SGAs should be used with caution in particular in the elderly 
due to their role in increasing the risk for hospitalization for 
acute kidney injury167 and hypotension with risk of falls, 
as documented by a cohort study involving older adults. 
On the other hand, antipsychotics with strong sedative 
effects can cause urinary incontinence, as can be the case 
with CLO, especially when associated with antipsychotic 
polypharmacotherapy.168,169 Although evidence on the topic is 
substantially lacking, nevertheless, the known adverse effects 
on kidney function after very long-term lithium treatment 
give rise to the recommendation that special caution be paid 
in patients on lithium combined with PALI, CLO, ILO, OLA, 
QUE, and RIS, a common drug regimen in evidence-based 
guidelines for BD.164,170 Finally, acute renal failure can occur 
in the context of rhabdomyolysis as a severe consequence of 
malignant neuroleptic syndrome, as described later.
Leucocytopenia, agranulocytosis, and 
thrombocytopenia
Neutropenia, thrombocytopenia, and agranulocytosis can 
typically occur not only with CLO and phenothiazine but 
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also with other antipsychotics such as RIS and QUE, in 
particular when the patient is on polypharmacotherapy with 
mood stabilizers.39,112 Case reports suggest that in patients 
with leukopenia (but not agranulocytosis), rechallenge with 
CLO is more often successful than not (70%), especially 
under co-treatment with low-dose lithium.113
Osteopenia, osteoporosis, and fractures
Bone mineral density in patients with schizophrenia treated 
with antipsychotics is negatively related with age and posi-
tively with duration of antipsychotic treatment and illness 
duration,171 ultimately increasing the risk of osteoporosis.172–174 
While preliminary data suggest an influence of elevated 
prolactin levels on bone turnover markers in schizophrenia 
treated with antipsychotics,175 suggesting that prolactin-
raising drugs should reduce bone mineral density,171 more 
studies are needed to better determine the precise mechanisms 
underlying the effect of antipsychotics on bone metabolism, 
as per an SR.176 Alongside with CVD, fractures explained 
part of the higher mortality with FGAs compared with SGAs 
in the elderly.121 However, fractures have been reported with 
all antipsychotics in patients with schizophrenia177 according 
to an SR. Osteopenia, osteoporosis, and fractures should be 
of particular concern in females during perimenopause when 
the risk for osteoporosis is elevated.
Falls
Considering that patients treated with antipsychotics have an 
increased risk for impaired bone metabolism for a number 
of reasons, including reduced physical activity and reduced 
sun exposure, falls due to side effects of AP can result in 
an increased risk of fractures, in particular within the first 
30 days of treatment.178 However, in elderly patients, antip-
sychotics seem to be associated with a lower risk of falls 
than either antidepressants179 or benzodiazepines in the first 
24 hours after the first administration.180 It remains difficult 
to establish whether the risk for falls with AP is due to seda-
tion, visual impairment, hypotension, or motor side effects, 
but most likely a multi-factorial model can best explain the 
increased risk. Data are lacking about the incidence of falls in 
adults with schizophrenia and BD, although it is known that 
this group is at an increased risk of fall-related fractures.177
Binge eating, pathological gambling, and 
impulse control disorders
Binge eating is linked to receptor affinity to histaminergic 
receptors and is frequently observed with the prescription of 
OLA and CLO according to an RCT.181 Because of its partial 
agonist effect on dopamine receptors, ARI may increase the 
risk of impulse control disorder, hypersexuality, compulsive 
shopping, and pathological gambling according to prelimi-
nary case report data and one epidemiological study.182–184 
Nevertheless, ARI usually has a net effect of dopamine 
antagonism, shown by worsening instead of improvement 
in motor symptoms in patients with Parkinson’s disease.185 
Hence, until more conclusive data exist and although the 
case reports may be related to symptoms of the disorders 
for which ARI was prescribed (as also indicated in the US 
Food and Drug Administration label of ARI), the risk for 
pathological gambling should be assessed when prescribing 
ARI to impulsive young patients with a history of substance 
abuse and to those with a high novelty-seeking profile.186
Tobacco use
Smoking is frequently a comorbidity in SMI,143 but antip-
sychotic treatment does not seem to increase the risk of 
smoking. Actually, both typical antipsychotics and CLO 
have been shown to increase the odds of smoking cessation 
in patients with schizophrenia.187,188 However, tobacco smoke 
increases the metabolism of several psychotropic medica-
tions through inducing enzymes in the cytochrome P450 
system, CYP1A2 in particular. Thus, the pharmacokinetics 
of OLA, and CLO are influenced in clinically relevant ways 
by smoking habits, in that smoking can decrease circulating 
drug levels, with a required increase of drug dose by up to 
50%189 and risk of overdose upon smoking cessation. The 
cognitive-enhancing properties of pulsatile nicotine delivery 
may constitute self-treatment by patients with SMI in an 
attempt to improve cognitive function, impaired due to both 
the disease and its treatment.190
Sexual and reproductive system 
dysfunction
Sexual dysfunction is frequent during antipsychotic treatment 
and can be due to several factors, including co-treatment 
with two dopamine D2 antagonists,191 long duration of ill-
ness, and TD in schizophrenia.192 Hyperprolactinemia can 
cause sexual and reproductive system dysfunction, including 
decreased libido, erectile dysfunction, and anorgasmia, as 
well as reproductive system dysfunction, such as gyneco-
mastia, galactorrhea, and oligo- or amenorrhea in women. 
All antipsychotics raise prolactin levels. AMI, RIS, and 
PALI do it the most.193–195 Conversely, drugs with a high 
α-adrenergic antagonism can induce priapism196,197 and 
retrograde ejaculation, which may be disturbing for patients 
prone to delusions.198,199 It should also be considered that 
drugs with a high sedative profile may indirectly diminish 
sexual arousal and desire.199 Restricted comparative data 
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limit conclusions about the relative ease with which different 
compounds affect sexual function.
endocrine diseases (diabetes ketoacidosis, 
hypothyroidism, and hyponatremia)
Although no relevant clinical studies are available, diabetic 
ketoacidosis is frequently reported in case reports of patients 
taking antipsychotics, in particular OLA, CLO, and RIS.200,201
Hypothyroidism can occur with QUE, ARI, RIS, or 
OLA, in patients treated for BD in a large cohort. However, 
the frequency of hypothyroidism with SGAs is lower than 
with lithium.202 While there are case reports of QUE being 
associated with thyroid dysfunction,203 no clinically relevant 
risk of thyroid disturbance has been described in association 
with antipsychotics.
Hyponatremia risk appears to be increased with antipsy-
chotic treatment and may be underestimated when several 
hyponatremia-inducing drugs are prescribed together, as 
reported in a large observational study.204 However, no 
solid literature provides comparative data for different com-
pounds, and no sodium monitoring is recommended when 
antipsychotics are started. In addition, hyponatremia may 
be related to polydipsia, a clinical feature often associated 
with schizophrenia.205
Hyperprolactinemia and prolactinoma
The degree of hyperprolactinemia depends on the D
2
 recep-
tor occupancy206 and on the antagonist properties of the 
antipsychotics.207 Thus, antipsychotics with a strong D
2
 affinity 
and antagonist pharmacodynamic properties increase prolactin 
serum levels the most, namely, AMI, HAL, PALI, and 
RIS.28,208 Moderate hyperprolactinemia has been described 
with SER, LUR, and ZIP; mild hyperprolactinemia has been 
described with ILO, CPZ, OLA, and ASE; and no hyperpro-
lactinemia has been seen with the use of QUE and CLO.28,209 
On the contrary, partial D2 agonists, such as ARI, BRE, and 
CAR, can lower prolactin levels, even below drug-free base-
line, and adjunctive ARI has been shown to decrease hyper-
prolactinemia associated with other antipsychotics.28,209–211 
Several cases have been reported describing antipsychotic use 
and prolactinoma,212 in particular in cases using AMI213,214 or 
RIS.215–217 However, no solid data are available, and thus, no 
conclusions can be drawn on the association of antipsychotics 
and prolactinoma.218
Breast and cervical cancers
Patients with SMI have lifestyle-related risk factors for cancer 
(smoking, caffeine intake, alcohol, lack of exercise) and 
often undergo less medical screening (for breast and cervical 
cancers for instance) than the general population.219,220 These 
factors could at least partially explain the higher cancer 
mortality rates,221 in particular for respiratory tumors,222 in 
patients with SMI, despite some evidence that suggests lower 
overall cancer rates.223 One mechanism that could contrib-
ute to an increased risk of tumorigenesis is antipsychotic- 
related hyperprolactinemia (for breast and prostate cancers). 
However, in two recent reviews, no causal linkage has 
been demonstrated between cervical and breast cancers and 
antipsychotics.224,225 Moreover, comparative data from a 
large, national representative dataset have shown that RIS 
does not confer a higher risk of breast cancer compared to 
other antipsychotics, either FGAs or SGAs, while controlling 
to some degree for illness and behavior-related risk factors in 
individuals receiving antipsychotics.226 Thus, no conclusive 
evidence supports an increased risk of cancer in relation to 
the use of antipsychotics in schizophrenia or BD.227
Neuroleptic malignant syndrome
Neuroleptic malignant syndrome (NMS) is characterized by 
hyperthermia, rigidity, elevated creatinine phosphokinase 
(CPK) more than four times of the upper limit (and up to 
myoglobinuria), changes in mental status, and autonomic 
dysregulation.204,228
While the exact incidence of NMS is unclear,229 it has 
potentially life-threatening consequences. NMS can occur 
with both FGAs and SGAs, in particular with the typical 
antipsychotics flupentixol, HAL, fluphenazine, thioridazine, 
CPZ, trifluoperazine, LOX, periciazine, methotrimepra-
zine, prochlorperazine, and zuclopenthixol, as well as with 
CLO, OLA, RIS, QUE, ARI, PALI, ASE, and ZIP.230 While 
no clear consensus exists,230 SGA-associated NMS seems to 
be of lower frequency, severity, duration, and lethality than 
NMS associated with FGAs.231,232 CLO may have the high-
est risk of NMS among SGAs,230 although patient-related 
factors may also play a role. Beyond specific pharmacologic 
compounds, several environmental factors can increase the 
risk of NMS, including the use of high doses, parenteral 
administration, polypharmacotherapy, physical restraint, 
dehydration, high temperature, older age and multiple 
medical comorbidities, previous history of NMS, family 
history of catatonia, and muscle channelopathy.230
Mortality
Several studies report that higher antipsychotic dosage and 
polypharmacy increase the risk of mortality in patients with 
schizophrenia,233 with a higher risk for FGAs compared to 
SGAs.121 Death is mediated by pneumonia, CVD, hip fracture, 
and cardiac arrhythmias, among other dysfunctions.121,137
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withdrawal and rebound syndromes
Withdrawal and rebound syndromes related to antipsychotic 
treatment depend on the pharmacokinetic and pharmacody-
namic profiles of the discontinued pre-switch antipsychotics 
and of the post-switch antipsychotics if withdrawal symptoms 
occur during antipsychotic switching. While the pharmacoki-
netic profile influences the timing of the occurrence of such 
syndromes, pharmacodynamics determines their symptom-
atic presentation.35 Withdrawal or rebound syndromes are 
central and peripheral phenomena induced by the sudden 
reversal of receptor blockade when the pre-switch medica-
tion is discontinued too quickly and the post-switch drug is 
a comparatively less efficient receptor antagonist.
One of the factors associated with withdrawal reac-
tions is plasma half-life. Generally, it takes approximately 
five times a compound’s half-life for it to be completely 
eliminated from plasma; such pharmacokinetic parameters 
should be taken into account when stopping a treatment or 
switching to a different antipsychotic. The antipsychotics 
with the shortest half-life are QUE immediate release and 
ZIP (,12 hours). ILO, AMI, CLO, HAL, and PER have a 
relatively short half-life (12–24 hours), while RIS/PALI and 
OLA have a moderately short one (20–36 hours). ARI, BRE, 
CAR, and SER have the longest half-lives (50–100 hours). 
The most important determinant of rebound is how long the 
drug attaches to the receptor; CLO for instance spends very 
little time at the receptor; OLA and QUE are the next shortest. 
Conversely, HAL attaches for a very long time.234
From a clinical perspective, upon withdrawal from a 
drug, one should expect peripheral manifestations opposite 
to those that were initially blocked by the drug. For example, 
one would expect diarrhea, sweating, nausea, vomiting, and 
hypotension when a medication with a strong anticholinergic 
activity is abruptly withdrawn or tachycardia and hyperten-
sion when an agent with potent alpha1 blocking potential 
is rapidly stopped. The rebound syndrome is caused by the 
exposure of a previously blocked and thus upregulated recep-
tor system to its natural ligand.35 Typically, histaminergic 
rebound includes anxiety, agitation, insomnia, restless-
ness, and EPS; cholinergic rebound is marked by agitation, 
confusion, and EPS; and dopaminergic rebound can manifest 
as increased psychotic symptoms, mania, agitation, aggres-
sion, akathisia, or dyskinesia.35 Hence, particular attention 
should be paid when switching from antipsychotics with 
strong antihistaminergic, anticholinergic, and/or antidop-
aminergic properties to those with lower affinities for these 
receptors. In addition to such “pharmacodynamic rebound” 
syndromes, “pharmacokinetic rebound” can occur when 
the post-switch antipsychotic is inadequately dosed or has a 
much longer half-life than the pre-switch antipsychotic. In 
this scenario, unless cross-titration is used, and depending 
on the relative half-lives of the discontinued and the new 
drug, the patient can suffer from temporary underdosing or 
overdosing.35,235
Pregnancy and breastfeeding
During pregnancy, OLA, CLO, and QUE, alongside with 
other antipsychotics, may be expected to increase the risk 
of gestational diabetes, hypertension, thromboembolism, 
or congenital malformations. However, evidence on the 
safety of these agents during pregnancy remains limited and 
conflicting. While an SR suggested the use of FGAs instead 
of SGAs during pregnancy, due to the fact that these latter 
agents may increase the risk of gestational diabetes and 
large-for-gestational-age babies,236 more recent large-scale 
observational studies do not confirm such a concern in terms 
of mother and newborn safety; these studies did, on the other 
hand, verify an increased risk for perinatal complications 
and low birth weight with FGAs.237,238 A recent expert panel 
recommended the use of OLA during pregnancy due to the 
large amount of safety data;239 the same panel suggested that 
QUE and RIS were also safe for use during pregnancy.239 
However, a recent large database study found that RIS use 
was associated with a small risk of cardiac and overall malfor-
mations even after adjustment to potential confounders.240
During breastfeeding, QUE, OLA, and ARI can be 
used; the relative infant doses (RIDs) for these agents are 
low (,2%).239 RIS may be used under medical supervision, 
while AMI and CLO should be avoided.195 Safety in lactation 
depends on the properties of the drug that determine its ease 
of passage into breast milk.
Sleepwalking and other sleep 
disturbances
Several case reports have described sleepwalking or other 
sleep disturbances (such as daytime sedation and sleep apnea 
described earlier) in association with antipsychotics adminis-
tration; however, it remains debatable whether antipsychotics 
contribute to the risk of sleep disturbances or may, in fact, 
help to reverse them.241 Overall, no definitive evidence is 
available on this matter.
Hypothermia
Increasingly, sporadic cases of hypothermia have been 
described when antipsychotics were administered; while a 
precise mechanism, namely, 5HT2 antagonism, has been 
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suggested, large studies with consistent (comparative) data 
are still lacking.242
Discussion
When assessing a medication, both efficacy and tolerability 
are equally important, not only because adverse effects 
can reduce subjective well-being and adherence but also 
because adverse effects can adversely affect treatment 
outcomes.50,243 Notwithstanding the fact that differences 
in efficacy among antipsychotics are relatively small 
and difficult to predict (with the one exception of CLO, 
which has shown a clear advantage over other agents for 
treatment-resistant schizophrenia), the ability to accurately 
predict differences in treatment-emergent adverse effects 
is critical. Such effects depend, at least in part, on distinct 
pharmacodynamic profiles of the various drugs.28,39,244 
Although the differentiation of antipsychotics into FGAs 
and SGAs is based on history and is overly simplistic, 
obscuring the different profiles of individual antipsychotics 
within each class that markedly diverge in their safety and 
tolerability profiles, this classification is still used and has 
some heuristic value. According to our review, generally, 
FGA-related adverse effects that affect symptomatic and 
functional outcomes include neuromotor disorders as well 
as the possibility of worsening negative symptoms, social 
withdrawal, and cognitive dysfunction. These effects may 
explain the lower adherence to FGAs compared to SGAs. 
However, the use of SGAs often leads to serious adverse 
cardiometabolic effects, individual agents carrying a differ-
ent propensity for weight gain and metabolic side effects. 
Importantly, the use of SGAs appears to be associated with 
less cognitive impairment than that of FGAs. With respect to 
management, treatment-emergent effects related to the use 
of FGAs, such as TD, are challenging to treat but the more 
common EPS respond well to anticholinergic medication. 
Sometimes, however, this is at the expense of worsening 
cognitive function. SGA-induced “metabolic” comorbidity 
can theoretically be prevented or reduced through the adop-
tion of a multidisciplinary approach of active monitoring 
plus careful attention to diet and activity level. However, 
diet alone does not prevent SGA-induced weight gain; 
although weight loss has been demonstrated,245,246 no evi-
dence of a positive dietary modulation of SGA-induced 
metabolic effects has thus far been evidenced.247 A meta-
analysis of physical exercise-based intervention for both 
BD and schizophrenia showed an increase in the physical 
activity of patients but no clear beneficial effects on physi-
cal parameters.248 A meta-analysis on mixed dietary and 
physical exercise interventions found very small positive 
effects (eg, a BMI reduction of 1 point). It is possible, 
however, that high heterogeneity and a relatively low qual-
ity of trials may have biased the results.249 Nevertheless, 
methodologically the best and largest individual RCT on 
this topic showed no real benefit of behavioral interventions 
on overall metabolic parameters.250
Important to keep in mind for the treatment of schizophre-
nia is that although FGAs and SGAs are equally effective in 
treating positive symptoms, negative and cognitive symp-
toms may be aggravated by FGAs.55,251 In the past, outcome 
measures were predominantly based on symptom reduction, 
but today, improvements in quality of life and overall func-
tional “recovery” constitute “real-world” therapeutic aims. 
Subjective measures are what matters most for current gold 
standards of outcome, and both negative and cognitive symp-
toms are more relevant here than the presence or absence of 
positive psychotic symptoms. For BD, the depressive polarity 
is most common252 and is also associated with a worse global 
outcome and with more functional impairment than is the 
presence of manic episodes.253 The evidence for antipsychotic 
efficacy in the treatment of depression in BD is sparse, except 
for positive reports on QUE, LUR, OLA, and CAR.254 There 
is strong evidence, however, for most SGAs of efficacy in 
the treatment of mania and manic-predominant polarity 
patients.255,256 The clinical challenge in the management 
of mania remains, nonetheless, because of poor treatment 
adherence and symptom control rooted in poor insight and 
comorbid substance abuse.257,258
Relying on the 50 years old yet still currently applicable 
theoretical framework of “behavioral toxicity”,47,48 we con-
clude that SGAs have broadened the range of therapeutic 
options in the treatment of schizophrenia and BD, rapidly 
gaining first-line rank, especially in international clinical 
guidelines for the evidence-based, long-term treatment of 
both schizophrenia and BD.170,259–261 The broad division 
of antipsychotics into FGAs and SGAs, although flawed, 
allows for individualized treatment choices that balance 
clinical and tolerability concerns. These choices, to date, 
are mostly limited to careful clinical observation and assess-
ment. Although modern, neurobiologically based instru-
ments – such as pharmacogenetic tests or biomarker-based 
decision making – have been developed, they are only, as 
yet, partially implemented. They currently show guarded 
promise for optimal selection of individually tailored antip-
sychotic agents.262,263
The limitation of this review is a dearth of informa-
tion on newer compounds, such as BRE, LUR, and CAR. 
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Furthermore, information about long-term effects is limited 
since most trials are of short duration. Data on the incidence 
of potentially serious adverse effects (NMS, agranulocytosis, 
diabetic ketoacidosis, pathological gambling, and pancrea-
titis) and on long-term side effects (eg, type 2 diabetes, TD, 
stroke, AMI, cancer, osteoporosis) remain inconclusive. 
Long-term effects on fetuses exposed in utero to these drugs 
remain unknown.
Using a framework that balances efficacy against target 
symptoms with the potential for behavioral toxicity, this 
review brings together what is currently known about the 
clinical use of antipsychotics. Methodologically improved 
clinical trials and large, prospective, longitudinal population-
based observational studies will, in the future, fill the gaps 
described earlier and provide further evidence on the safety 
and tolerability of antipsychotic medications.
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